SIBO and Dysautonomia: Small Intestinal Bacterial Overgrowth as a Driver of Autonomic Symptoms

Small intestinal bacterial overgrowth (SIBO) — a condition in which bacteria that normally reside in the colon colonize the small intestine in excessive numbers — is increasingly recognized as both a cause and consequence of dysautonomia. The gut-autonomic nervous system connection is bidirectional: autonomic dysfunction impairs gut motility and creates conditions that favor SIBO, while SIBO produces bacterial toxins and inflammatory mediators that can worsen autonomic dysfunction.

How Dysautonomia Causes SIBO

The small intestine is normally kept relatively free of bacteria by the migrating motor complex (MMC) — a pattern of muscular contractions that sweeps the small intestine clean between meals, moving bacteria and undigested food toward the colon. The MMC is regulated by the enteric nervous system and the vagus nerve.

In dysautonomia — particularly POTS and vagal dysfunction — the MMC is impaired. Reduced vagal tone slows the MMC, allowing bacteria to accumulate in the small intestine. Gastroparesis (delayed gastric emptying), which is common in dysautonomia, further impairs the clearance of bacteria from the upper gastrointestinal tract.

Additionally, many medications used to treat dysautonomia — including proton pump inhibitors (which reduce stomach acid, a natural barrier to bacterial colonization) and opioids (which slow gut motility) — increase SIBO risk.

How SIBO Worsens Dysautonomia

SIBO produces a range of bacterial toxins and inflammatory mediators that can worsen autonomic dysfunction:

Hydrogen and methane gas. Bacteria in the small intestine ferment carbohydrates, producing hydrogen and methane gas. These gases cause bloating, abdominal distension, and pain, and may directly affect gut motility and the enteric nervous system.

Lipopolysaccharide (LPS). Gram-negative bacteria in the small intestine produce LPS (endotoxin), which can cross the intestinal barrier and enter the bloodstream, triggering systemic inflammation. Systemic LPS activates the sympathetic nervous system and impairs baroreceptor function, potentially worsening POTS.

Histamine production. Many bacteria in the small intestine produce histamine from dietary histidine. SIBO can dramatically increase histamine production, worsening MCAS symptoms and contributing to flushing, headache, and gastrointestinal symptoms.

Bile acid dysregulation. SIBO disrupts normal bile acid metabolism, which can impair fat absorption, worsen diarrhea, and affect the gut-brain axis.

Symptoms of SIBO in Dysautonomia Patients

SIBO symptoms overlap significantly with other dysautonomia-related gastrointestinal symptoms, making diagnosis challenging:

• Bloating and abdominal distension (often worsened after meals)
• Abdominal pain and cramping
• Diarrhea, constipation, or alternating bowel habits
• Nausea
• Fatigue (often worsened after eating)
• Brain fog (often worsened after eating)
• Nutritional deficiencies (B12, fat-soluble vitamins)
• Unintentional weight loss

A key clue to SIBO is symptoms that are worsened by eating — particularly foods high in fermentable carbohydrates (FODMAPs, fiber) — and improved by fasting.

Diagnosis

Breath testing. The standard diagnostic test for SIBO is a breath test that measures hydrogen and/or methane gas after ingestion of a fermentable substrate (lactulose or glucose). Elevated hydrogen or methane levels indicate bacterial fermentation in the small intestine.

Small intestinal aspirate and culture. The gold standard for SIBO diagnosis is direct aspiration and culture of small intestinal fluid, which can quantify bacterial counts and identify the organisms present. This test is invasive and not widely available.

Clinical diagnosis. Many clinicians diagnose SIBO clinically based on symptoms and response to treatment, particularly when breath testing is unavailable or inconclusive.

Treatment

Antibiotics. The first-line treatment for SIBO is antibiotics that target the small intestinal bacteria:

• Rifaximin (non-absorbable antibiotic): Effective for hydrogen-dominant SIBO; minimal systemic absorption reduces side effects.
• Rifaximin + neomycin or metronidazole: Used for methane-dominant SIBO (now called intestinal methanogen overgrowth, IMO).

Elemental diet. A 2–3 week elemental diet (pre-digested liquid nutrition that is absorbed before reaching the bacteria) can eradicate SIBO in approximately 80% of patients and is an alternative to antibiotics for patients who cannot tolerate them.

Prokinetics. After treating SIBO, prokinetic medications (low-dose erythromycin, prucalopride, low-dose naltrexone) can restore MMC function and reduce SIBO recurrence.

Dietary modification. A low-FODMAP diet reduces the fermentable substrate available to bacteria and can reduce symptoms, though it does not treat the underlying SIBO.

Addressing the underlying dysautonomia. Improving autonomic function — through POTS treatment, vagal nerve stimulation, or other interventions — can improve MMC function and reduce SIBO recurrence.

ChatDys resources: Track your gastrointestinal symptoms and meal-related patterns in the Health Tracker. Upload your breath test results to Biomarkers. Review our gut-brain axis dysautonomia guide and our low-FODMAP diet for POTS article for more information.